title: Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.
abstract: To assess the efficacy and safety of maraviroc (MVC) administered once-daily in routine clinical practice. A retrospective multicenter study (27 centers in Spain) was conducted. Data were collected from the records of patients starting a regimen with MVC. Laboratory and clinical data were recorded every 3 months the first year and every 6 months thereafter. Data are presented as median and interquartile range. Among 667 patients treated with MVC, 142 (21.3%) received MVC once-daily: 108 (76.1%), 150 mg and 34 (23.9%), and 300 mg. Age was 47 (42-45) years, there were 76.1% men, and 81 (57%) patients had baseline HIV-RNA <50 copies/mL. Viral tropism was R5 in 118 (83.1%) patients. Reasons for prescribing MVC: salvage therapy (36.6%), drug toxicity (31.2%), simplification (16.9%), and immunodiscordant response (7.1%). Median follow-up was 13 (9-16) months. In 95.8%, a PI/r was part of the regimen (67% on dual therapy). At months 12 and 24, 73.3% and 68.2% of patients had HIV-RNA <50 copies/mL, respectively (p = .041 and p < .001 vs. baseline). CD4+cell count increased by a median of 52 (-36,135) and 84 (-9.5,180) cells/mm3at 12 and 24 months, respectively (p < .001 and p = .039 vs. baseline). Twenty-five (17.6%) patients discontinued MVC: virologic failure (6), medical decision (5), and other reasons (14). Two patients presented grade 3 adverse events (hypertransaminasemia, hypertriglyceridemia) without the need for MVC withdrawal, whereas MVC was discontinued in two patients due to gastrointestinal toxicity. In routine clinical practice, MVC once-daily combined with at least PI/r was virologically effective and well tolerated in a high percentage of pretreated patients.
authors.affiliation: 1 HIV and STD Unit, Infectious Diseases Service, Bellvitge University Hospital , Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain .
authors.forename: Maria
authors.initials: M
authors.lastname: Saumoy
authors.affiliation: 2 Hospital Universitari Germans Trias i Pujol , Badalona, Spain .|3 Universitat Autònoma de Barcelona , Barcelona, Spain .
authors.forename: Josep M
authors.initials: JM
authors.lastname: Llibre
authors.affiliation: 4 Infectious Diseases Unit, Hospital SAS , Jerez de la Frontera, Spain .
authors.forename: Alberto
authors.initials: A
authors.lastname: Terrón
authors.affiliation: 5 Infectious Diseases Department, Hospital del Mar , Barcelona, Spain .
authors.forename: Hernando
authors.initials: H
authors.lastname: Knobel
authors.affiliation: 6 Internal Medice Services, Hospital Universitario La Paz-IdiPAZ , Madrid, Spain .
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Arribas
authors.affiliation: 7 Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau , Barcelona, Spain .
authors.forename: Pere
authors.initials: P
authors.lastname: Domingo
authors.affiliation: 8 Clinical Biostatistics Unit, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) , Madrid, Spain .
authors.forename: David
authors.initials: D
authors.lastname: Arroyo-Manzano
authors.affiliation: 9 Hospital Reina Sofía-IMIBIC , Córdoba, Spain .
authors.forename: Antonio
authors.initials: A
authors.lastname: Rivero
authors.affiliation: 10 Hospital Ramón y Cajal-IRYCIS , Madrid, Spain .
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.affiliation: 1 HIV and STD Unit, Infectious Diseases Service, Bellvitge University Hospital , Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain .
authors.forename: Daniel
authors.initials: D
authors.lastname: Podzamczer
mesh_terms: D000328:Adult; D065100:CCR5 Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D018791:CD4 Lymphocyte Count; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000473:pathology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D013030:Spain; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D019562:Viral Load
chemical_list: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D012367:RNA, Viral; D014230:Triazoles; D000077592:Maraviroc
keywords: efficacy; maraviroc once-daily; routine clinical practice; safety